These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37546147)

  • 1. Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients.
    Rizwan MZ; Garcia R; Mara K; Nei S
    Cureus; 2023 Jul; 15(7):e41422. PubMed ID: 37546147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
    Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
    Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response.
    Tack J; Lappalainen J; Diva U; Tummala R; Sostek M
    United European Gastroenterol J; 2015 Oct; 3(5):471-80. PubMed ID: 26535126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxegol , a new drug for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of naloxegol in the management of opioid-induced bowel dysfunction.
    Leppert W; Woron J
    Therap Adv Gastroenterol; 2016 Sep; 9(5):736-46. PubMed ID: 27582887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
    Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K
    Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of oral naloxegol vs subcutaneous methylnaltrexone in treatment of opioid-induced constipation in the hospital setting.
    Nero R; Allen B; Hailu K; Noor R; Theiss K
    Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S70-S76. PubMed ID: 36440903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
    Webster L; Tummala R; Diva U; Lappalainen J
    J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.
    Lemaire A; Pointreau Y; Narciso B; Piloquet FX; Braniste V; Sabaté JM
    Support Care Cancer; 2021 Dec; 29(12):7577-7586. PubMed ID: 34120247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxegol for the treatment of opioid-induced constipation.
    Tack J; Corsetti M
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxegol for opioid-induced constipation in patients with noncancer pain.
    Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
    N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB; Kowey P; Diva U; Sostek M; Tummala R
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
    Lawson R; King F; Marsh K; Altincatal A; Cimen A
    Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation.
    Brenner DM; Hu Y; Datto C; Creanga D; Camilleri M
    Am J Gastroenterol; 2019 Jun; 114(6):954-963. PubMed ID: 31058652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies.
    Chey WD; Brenner DM; Cash BD; Hale M; Adler J; Jamindar MS; Rockett CB; Almenoff JS; Bortey E; Gudin J
    J Pain Res; 2023; 16():2943-2953. PubMed ID: 37664485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation-The NACASY Study.
    Davies A; Cinieri S; Dupoiron D; España Fernandez S; Leclerc J; Montesarchio V; Mystakidou K; Serna J; Tack J; On Behalf Of The Nacasy Study Group
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripherally acting μ-opioid receptor antagonists for treatment of opioid-induced constipation in children.
    Novak C; Hogg A; Sue K; Davies D
    Paediatr Child Health; 2021; 26(2):e105-e109. PubMed ID: 33747318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
    Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
    J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.